Vaxcyte (PCVX) Accounts Payables (2019 - 2026)

Vaxcyte (PCVX) has reported Accounts Payables for 8 consecutive years, with $63.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 207.4% year-over-year to $63.1 million; the TTM figure through Mar 2026 stood at $63.1 million (up 207.4% YoY), while the FY2025 annual figure was $70.9 million, up 46.34% from the prior year.
• Accounts Payables slipped to $63.1 million in Q1 2026 per PCVX's latest filing, from $70.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $70.9 million in Q4 2025 and bottomed at $4.8 million in Q1 2022.
• Historically, Accounts Payables has averaged $24.6 million across 5 years, with a median of $16.3 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 84.93% — and 2024, when it jumped 232.16%.
• Vaxcyte's Accounts Payables stood at $9.8 million in 2022, then surged by 48.92% to $14.6 million in 2023, then surged by 232.16% to $48.5 million in 2024, then jumped by 46.34% to $70.9 million in 2025, then fell by 11.06% to $63.1 million in 2026.
• Business Quant data shows PCVX's Accounts Payables at $63.1 million in Q1 2026, $70.9 million in Q4 2025, and $49.0 million in Q3 2025.